批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2018/03/23 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/03/23 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/05/22 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/07/27 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/02/26 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/10/07 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/04/07 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/12/20 |
SUPPL-15(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2012/05/30 |
SUPPL-14(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2011/06/16 |
SUPPL-12(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/06/16 |
SUPPL-10(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/06/16 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/06/16 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/06/16 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/06/16 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/07/09 |
SUPPL-8(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2010/04/26 |
SUPPL-6(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2007/11/09 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2007/05/30 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:TEMSIROLIMUS 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:25MG/ML (25MG/ML) 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022088 |
001 |
NDA |
TORISEL |
TEMSIROLIMUS |
SOLUTION;INTRAVENOUS |
25MG/ML (25MG/ML) |
Prescription |
Yes |
Yes |
AP |
2007/05/30
|
PF PRISM CV |
203153 |
001 |
ANDA |
TEMSIROLIMUS |
TEMSIROLIMUS |
SOLUTION;INTRAVENOUS |
25MG/ML (25MG/ML) |
Prescription |
No |
No |
AP |
2018/07/30
|
ACCORD HLTHCARE |
207383 |
001 |
ANDA |
TEMSIROLIMUS |
TEMSIROLIMUS |
SOLUTION;INTRAVENOUS |
25MG/ML (25MG/ML) |
Prescription |
No |
No |
AP |
2019/08/16
|
GLAND PHARMA LTD |